Complement mediated hepatocytes injury in a model of autoantibody induced hepatitis

Immunobiology

Volumn 216, Issue 4, 2011, Pages 528-534

  Tu, Zhidan ^a,c   Li, Qing ^a   Chou, Hong Shiue ^b   Hsieh, Ching Chuang ^b   Meyerson, Howard ^a   Peters, Marion G ^d   Bu, Hong ^c   Fung, John J ^b   Qian, Shiguang ^b   Lu, Lina ^b   Lin, Feng ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c SICHUAN UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoantibody; Autoimmune hepatitis; Complement; Complement regulators

Indexed keywords

ALANINE AMINOTRANSFERASE; AUTOANTIBODY; COBROTOXIN; COMPLEMENT; COMPLEMENT INHIBITOR; DECAY ACCELERATING FACTOR; IMMUNOGLOBULIN G; OVALBUMIN; POLYCLONAL ANTIBODY;

ADOPTIVE TRANSFER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE HEPATITIS; C57BL 6 MOUSE; CELL SURFACE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CELL DAMAGE; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD55; ANTIGENS, CD59; AUTOANTIBODIES; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; HEPATITIS, AUTOIMMUNE; HEPATOCYTES; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, COMPLEMENT;

EID: 79952192141     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2010.08.004     Document Type: Article

References (34)

1. Bouron-Dal Soglio D., Rougemont A.L., Herzog D., Soucy G., Alvarez F., Fournet J.C. An immunohistochemical evaluation of C4d deposition in pediatric inflammatory liver diseases. Hum. Pathol. 2008, 39:1103.
2. Buxbaum J., Qian P., Allen P.M., Peters M.G. Hepatitis resulting from liver-specific expression and recognition of self-antigen. J. Autoimmun. 2008, 31:208.
3. Czaja A.J. Autoimmune liver disease. Curr. Opin. Gastroenterol. 2008, 24:298.
4. Czaja A.J. Progress in the diagnosis and treatment of autoimmune hepatitis. Minerva Med. 2008, 99:549.
5. Czaja A.J. Autoimmune liver disease. Curr. Opin. Gastroenterol. 2009, 25:215.
6. Ferrone S., Cooper N.R., Pellegrino M.A., Reisfeld R.A. Activation of human complement by human lymphoid cells sensitized with histocompatibility alloantisera. Proc. Natl. Acad. Sci. U.S.A. 1973, 70:3665.
7. Foley S., Li B., Dehoff M., Molina H., Holers V.M. Mouse Crry/p65 is a regulator of the alternative pathway of complement activation. Eur. J. Immunol. 1993, 23:1381.
8. Halme J., Sachse M., Vogel H., Giese T., Klar E., Kirschfink M. Primary human hepatocytes are protected against complement by multiple regulators. Mol. Immunol. 2009, 46:2284.
9. Kolber M.A., Quinones R.R., Gress R.E., Henkart P.A. Measurement of cytotoxicity by target cell release and retention of the fluorescent dye bis-carboxyethyl-carboxyfluorescein (BCECF). J. Immunol. Methods 1988, 108:255.
10. Krawitt E.L. Autoimmune hepatitis. N. Engl. J. Med. 2006, 354:54.
11. Kaminski H.J., Kusner L.L., Richmonds C., Medof M.E., Lin F. Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Minerva Exp. Neurol. 2006, 202:287.
12. Li Q., Nacion K., Bu H., Lin F. Mouse CD4+ CD25+ T regulatory cells are protected from autologous complement mediated injury by Crry and CD59. Biochem. Biophys. Res. Commun. 2009, 382:223.
13. Lin F., Fukuoka Y., Spicer A., Ohta R., Okada N., Harris C.L., Emancipator S.N., Medof M.E. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology 2001, 104:215.
14. Lin F., Immormino R.M., Shoham M., Medof M.E. Bulk production and functional analyses of mouse CD55's native and deglycosylated active domains. Arch. Biochem. Biophys. 2001, 393:67.
15. Lohr H., Treichel U., Poralla T., Manns M., Meyer zum Buschenfelde K.H. Liver-infiltrating T helper cells in autoimmune chronic active hepatitis stimulate the production of autoantibodies against the human asialoglycoprotein receptor in vitro. Clin. Exp. Immunol. 1992, 88:45.
16. Li B., Sallee C., Dehoff M., Foley S., Molina H., Holers V.M. Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J. Immunol. 1993, 151:4295.
17. Lin F., Kaminski H.J., Conti-Fine B.M., Wang W., Richmonds C., Medof M.E. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J. Clin. Invest. 2002, 110:1269.
18. Medof M.E., Kinoshita T., Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J. Exp. Med. 1984, 160:1558.
19. Miwa T., Nonaka M., Okada N., Wakana S., Shiroishi T., Okada H. Molecular cloning of rat and mouse membrane cofactor protein (MCP, CD46): preferential expression in testis and close linkage between the mouse Mcp and Cr2 genes on distal chromosome 1. Immunogenetics 1998, 48:363.
20. Minuk G.Y., Liu S., Kaita K., Wong S., Renner E., Rempel J., Uhanova J. Autoimmune hepatitis in a North American Aboriginal/First Nations population. Can. J. Gastroenterol. 2008, 22:829.
21. Nicholson-Weller A., Russian D.A., Austen K.F. Natural killer cells are deficient in the surface expression of the complement regulatory protein, decay accelerating factor (DAF). J. Immunol. 1986, 137:1275.
22. Qin X., Gao B. The complement system in liver diseases. Cell. Mol. Immunol. 2006, 3:333.
23. Seya T., Ballard L.L., Bora N.S., Kumar V., Cui W., Atkinson J.P. Distribution of membrane cofactor protein of complement on human peripheral blood cells. An altered form is found on granulocytes. Eur. J. Immunol. 1988, 18:1289.
24. Scoazec J.Y., Delautier D., Moreau A., Durand F., Degott C., Benhamou J.P., Belghiti J., Feldmann G. Expression of complement-regulatory proteins in normal and UW-preserved human liver. Gastroenterology 1994, 107:505.
25. Spiller O.B., Criado-Garcia O., Rodriguez De Cordoba S., Morgan B.P. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin. Exp. Immunol. 2000, 121:234.
26. Seya T., Turner J.R., Atkinson J.P. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J. Exp. Med. 1986, 163:837.
27. Sahu A., Lambris J.D. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology 2000, 49:133.
28. Spiller O.B., Harris C.L., Morgan B.P. Efficient generation of monoclonal antibodies against surface-expressed proteins by hyperexpression in rodent cells. J. Immunol. Methods 1999, 224:51.
29. Treichel U., McFarlane B.M., Seki T., Krawitt E.L., Alessi N., Stickel F., McFarlane I.G., Kiyosawa K., Furuta S., Freni M.A., et al. Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology 1994, 107:799.
30. Yamauchi K., Yamaguchi N., Furukawa T., Takatsu K., Nakanishi T., Sasaki M., Isono E., Tokushige K., Komatsu T., Shiratori K. A novel IgM class autoantibody to a hepatocyte-related 190kDa molecule in patients with type 1 autoimmune hepatitis. Hepatology 2004, 40:687.
31. Zhao Y., Ding W.X., Qian T., Watkins S., Lemasters J.J., Yin X.M. Bid activates multiple mitochondrial apoptotic mechanisms in primary hepatocytes after death receptor engagement. Gastroenterology 2003, 125:854.
32. Yamauchi K., Yamaguchi N., Furukawa T., Takatsu K., Nakanishi T., Ishida K., Komatsu T., Tokushige K., Nagahara H., Hashimoto E., Shiratori K. A murine model of acute liver injury induced by human monoclonal autoantibody. Hepatology 2005, 42:149.
33. Zalman L.S., Wood L.M., Muller-Eberhard H.J. Inhibition of antibody-dependent lymphocyte cytotoxicity by homologous restriction factor incorporated into target cell membranes. J. Exp. Med. 1987, 166:947.
34. Zhou Y., Gong B., Lin F., Rother R.P., Medof M.E., Kaminski H.J. Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J. Immunol. 2007, 179:8562.